Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, single center study to assess the pharmacokinetics, safety and tolerability of multiple administrations of 30 mg PMI-150 (intranasal ketamine) in healthy adult volunteers

Next Previous
X
Search
Trial Profile

An open label, single center study to assess the pharmacokinetics, safety and tolerability of multiple administrations of 30 mg PMI-150 (intranasal ketamine) in healthy adult volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 15 Aug 2008

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ketamine (Primary)
  • Indications Acute pain; Cancer pain
  • Focus Pharmacokinetics
  • Sponsors Javelin Pharmaceuticals

    • Most Recent Events

    • 13 Aug 2008 Pharmacokinetic data presented at the Department of Defense's 2008 Advanced Technology Applications for Combat Casualty Care (ATACCC) Conference.
    • 31 Aug 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top